Impressive response to dual BRAF and MEK inhibition in patients with BRAF mutant intrahepatic cholangiocarcinoma-2 case reports and a brief review.
暂无分享,去创建一个
[1] C. Atreya,et al. Combined BRAF and MEK Inhibition With Dabrafenib and Trametinib in BRAF V600-Mutant Colorectal Cancer. , 2015, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[2] J. Blay,et al. Vemurafenib in Multiple Nonmelanoma Cancers with BRAF V600 Mutations. , 2015, The New England journal of medicine.
[3] J. Berlin,et al. Biliary tract cancers: understudied and poorly understood. , 2015, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[4] G. Mills,et al. Mutation Profiling in Cholangiocarcinoma: Prognostic and Therapeutic Implications , 2014, PloS one.
[5] K. Flaherty,et al. Combined BRAF (Dabrafenib) and MEK inhibition (Trametinib) in patients with BRAFV600-mutant melanoma experiencing progression with single-agent BRAF inhibitor. , 2014, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[6] E. Furth,et al. Dramatic response to dabrafenib and trametinib combination in a BRAF V600E-mutated cholangiocarcinoma: implementation of a molecular tumour board and next-generation sequencing for personalized medicine , 2014, Ecancermedicalscience.
[7] A. Warth,et al. BRAF V600E-specific immunohistochemistry reveals low mutation rates in biliary tract cancer and restriction to intrahepatic cholangiocarcinoma , 2014, Modern Pathology.
[8] A. Ejaz,et al. Genomic Profiling of Intrahepatic Cholangiocarcinoma: Refining Prognosis and Identifying Therapeutic Targets , 2014, Annals of Surgical Oncology.
[9] Timothy M Pawlik,et al. The frequency of KRAS and BRAF mutations in intrahepatic cholangiocarcinomas and their correlation with clinical outcome. , 2013, Human pathology.
[10] D. Cunningham,et al. Cisplatin plus gemcitabine versus gemcitabine for biliary tract cancer. , 2010, The New England journal of medicine.
[11] F. Sommerer,et al. Mutations of the BRAF gene in cholangiocarcinoma but not in hepatocellular carcinoma , 2003, Gut.